Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 23 of 2499 for:    CARBON DIOXIDE

Carbon Dioxide Versus Air Insufflation for the Application of Argon Plasma to Reduce the Gastrojejunal Anastomosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03264027
Recruitment Status : Recruiting
First Posted : August 28, 2017
Last Update Posted : May 27, 2019
Sponsor:
Information provided by (Responsible Party):
Luiz Gustavo de Quadros, MD, Kaiser Clinic and Hospital

Brief Summary:
The objective of this randomized clinical trial is to compare pain levels during and after insufflation with carbon dioxide or in subjects that will undergo endoscopic fulguration with argon to reduce the diameter of the gastrojejunal anastomosis. The investigators hypothesize that carbon dioxide will be superior in causing less pain and leading to less discomfort.

Condition or disease Intervention/treatment Phase
Dilatation of Anastomosis Bypass Complication Obesity Drug: Carbon dioxide Drug: Ambient air Drug: Argon fulguration Not Applicable

Detailed Description:

Laparoscopic gastric bypass surgery is one of the strategies oriented towards weight reduction in obese patients. Although in the short term it has a high degree of success, weight regain is common in the long term, in part due to the dilatation of the anastomosis that allows food to pass without barriers and hinders the purpose of bypass surgery. Fulguration with argon is an endoscopic technique that reduces the diameter of the anastomosis, offering resistance to food passage and improving patient outcomes.

Although carbon dioxide is the current standard for laparoscopic surgery, its use for fulguration with argon as compared to ambient air has not been investigated in the setting of the stenosis of a dilated anastomosis following gastric bypass surgery. stenosis. Therefore, to investigate pain during and after this procedure, investigators will conduct a randomized clinical trial comparing carbon dioxide and ambient air.

The secondary aims will be to measure the diameter of the gastrojejunal anastomosis during three endoscopic sessions and in a final control examination eight weeks after the third session; to determine whether the patient loses weight or not by the final control objective after three sessions of endoscopic fulguration with argon; to analyze if the method employed is able to reduce body weight to the minimum weight achieved after bariatric surgery;and to investigate whether there is a correlation between the percentage reduction in anastomotic diameter and the percentage loss of regained weight.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Both the participant and the outcome assessor will be blinded to the study intervention.
Primary Purpose: Treatment
Official Title: A Multicenter Randomized Clinical Trial of Carbon Dioxide (CO2) Versus Air Insufflation for the Application of Argon Plasma to Reduce the Gastrojejunal Anastomosis in Individuals With Weight Regain After Bypass Surgery.
Actual Study Start Date : January 6, 2017
Estimated Primary Completion Date : January 12, 2020
Estimated Study Completion Date : January 12, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Carbon dioxide
Argon fulguration will be performed using CO2 for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
Drug: Carbon dioxide
Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
Other Name: Carbon dioxide insufflation

Drug: Argon fulguration
The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
Other Name: Argon

Active Comparator: Ambient air
Argon fulguration will be performed using ambient air for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
Drug: Ambient air
Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
Other Name: Ambient air insuflattion

Drug: Argon fulguration
The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
Other Name: Argon




Primary Outcome Measures :
  1. Change in Pain Visual Analogue Scale [ Time Frame: Before surgery, and after eight weeks of the first endoscopic session. The outcome will be the substraction of the initial value and the final value of pain. ]
    A visual scale to assess self-reported pain going from 0 to 10.


Secondary Outcome Measures :
  1. Change in diameter of the gastrojejunal anastomosis [ Time Frame: Before surgery, and after eight weeks of the first endoscopic session. ]
    Analysis and measurement in millimeters of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA).

  2. Weight reduction [ Time Frame: Before surgery, and after eight weeks of the first endoscopic session. ]
    The final weight measured in kilograms after eight weeks of the initial surgery will be subtracted from the weight at the start of the trial



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Regain of at least 10.0% of the minimum weight reached after the gastric bypass;
  • Ability to understand study procedures;
  • Signed the informed written consent form;
  • Possible to complete all the stages of the study.

Exclusion Criteria:

  • Presence of very tight restrictive ring preventing the advancement of the endoscopy device;
  • Stenosis of the anastomosis preventing the progression of the endoscopy device before the end of the three endoscopic sessions;
  • History of liver diseases such as cirrhosis or chronic active hepatitis;
  • Patients who required anticoagulant therapy with the exception of antiplatelet agents;
  • Pregnant women or those intending to become pregnant within 12 months after fulguration with argon;
  • Participant in another ongoing clinical research;
  • Recent history of neoplasia (less than 5 years);
  • Alcoholism or drug use;
  • HIV positive;
  • Unbalanced or uncontrollable psychiatric disorders;
  • Anemia or severe nutritional deficiencies;
  • Allergy to anesthetic compounds;
  • Impossibility to return within defined periods for consultations and endoscopic sessions of fulguration with argon;
  • Inability to follow nutritional guidelines after each endoscopic session;
  • Inability to understand study procedures;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03264027


Contacts
Layout table for location contacts
Contact: Luiz G Quadros, MD 5517981388737 gustavo_quadros@hotmail.com

Locations
Layout table for location information
Brazil
Kaiser Clinic and Day Hospital Recruiting
São José do Rio Prêto, Sao Paolo, Brazil, 15015-110
Contact: Luiz G Quadros, MD    5517981388737    gustavo_quadros@hotmail.com   
Sponsors and Collaborators
Kaiser Clinic and Hospital
Investigators
Layout table for investigator information
Principal Investigator: Luiz G Quadros, MD Kaiser Clinic and Hospital

Publications:
Layout table for additonal information
Responsible Party: Luiz Gustavo de Quadros, MD, MD, Kaiser Clinic and Hospital
ClinicalTrials.gov Identifier: NCT03264027     History of Changes
Other Study ID Numbers: kaiserargongjanastomosis
First Posted: August 28, 2017    Key Record Dates
Last Update Posted: May 27, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Aneurysm
Dilatation, Pathologic
Vascular Diseases
Cardiovascular Diseases
Pathological Conditions, Anatomical